| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.29 | 9e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0003 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0004 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.14 | 0.006 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.007 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.007 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.008 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.01 |